Contemporary Management of Pineoblastoma

Matthew C. Tate, Martin J. Rutkowski, Andrew T. Parsa*

*Corresponding author for this work

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Pineoblastomas (PBs) represent the most aggressive of the pineal parenchymal tumors. Routine treatment consists of operative management of obstructive hydrocephalus and cerebrospinal fluid studies followed by maximal resection and adjuvant chemotherapy/radiotherapy, resulting in a median survival of 20 months. Important prognostic factors for survival of patients with PB include extent of resection, age at presentation, disseminated disease, and craniospinal radiotherapy. Novel strategies being evaluated for the treatment of PB include high-dose chemotherapy with autologous stem cell therapy, stereotactic radiosurgery, and histone deacetylase inhibitors.

Original languageEnglish (US)
Pages (from-to)409-412
Number of pages4
JournalNeurosurgery Clinics of North America
Volume22
Issue number3
DOIs
StatePublished - Jul 1 2011

Fingerprint

Pinealoma
Adjuvant Radiotherapy
Histone Deacetylase Inhibitors
Survival
Radiosurgery
Adjuvant Chemotherapy
Hydrocephalus
Cell- and Tissue-Based Therapy
Cerebrospinal Fluid
Radiotherapy
Stem Cells
Drug Therapy
Therapeutics

Keywords

  • Pineoblastoma
  • Survival
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Tate, Matthew C. ; Rutkowski, Martin J. ; Parsa, Andrew T. / Contemporary Management of Pineoblastoma. In: Neurosurgery Clinics of North America. 2011 ; Vol. 22, No. 3. pp. 409-412.
@article{160aa24e2ecf4ffbbb32ad4334fc99b0,
title = "Contemporary Management of Pineoblastoma",
abstract = "Pineoblastomas (PBs) represent the most aggressive of the pineal parenchymal tumors. Routine treatment consists of operative management of obstructive hydrocephalus and cerebrospinal fluid studies followed by maximal resection and adjuvant chemotherapy/radiotherapy, resulting in a median survival of 20 months. Important prognostic factors for survival of patients with PB include extent of resection, age at presentation, disseminated disease, and craniospinal radiotherapy. Novel strategies being evaluated for the treatment of PB include high-dose chemotherapy with autologous stem cell therapy, stereotactic radiosurgery, and histone deacetylase inhibitors.",
keywords = "Pineoblastoma, Survival, Treatment",
author = "Tate, {Matthew C.} and Rutkowski, {Martin J.} and Parsa, {Andrew T.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1016/j.nec.2011.05.001",
language = "English (US)",
volume = "22",
pages = "409--412",
journal = "Neurosurgery Clinics of North America",
issn = "1042-3680",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Contemporary Management of Pineoblastoma. / Tate, Matthew C.; Rutkowski, Martin J.; Parsa, Andrew T.

In: Neurosurgery Clinics of North America, Vol. 22, No. 3, 01.07.2011, p. 409-412.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Contemporary Management of Pineoblastoma

AU - Tate, Matthew C.

AU - Rutkowski, Martin J.

AU - Parsa, Andrew T.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Pineoblastomas (PBs) represent the most aggressive of the pineal parenchymal tumors. Routine treatment consists of operative management of obstructive hydrocephalus and cerebrospinal fluid studies followed by maximal resection and adjuvant chemotherapy/radiotherapy, resulting in a median survival of 20 months. Important prognostic factors for survival of patients with PB include extent of resection, age at presentation, disseminated disease, and craniospinal radiotherapy. Novel strategies being evaluated for the treatment of PB include high-dose chemotherapy with autologous stem cell therapy, stereotactic radiosurgery, and histone deacetylase inhibitors.

AB - Pineoblastomas (PBs) represent the most aggressive of the pineal parenchymal tumors. Routine treatment consists of operative management of obstructive hydrocephalus and cerebrospinal fluid studies followed by maximal resection and adjuvant chemotherapy/radiotherapy, resulting in a median survival of 20 months. Important prognostic factors for survival of patients with PB include extent of resection, age at presentation, disseminated disease, and craniospinal radiotherapy. Novel strategies being evaluated for the treatment of PB include high-dose chemotherapy with autologous stem cell therapy, stereotactic radiosurgery, and histone deacetylase inhibitors.

KW - Pineoblastoma

KW - Survival

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=79960707095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960707095&partnerID=8YFLogxK

U2 - 10.1016/j.nec.2011.05.001

DO - 10.1016/j.nec.2011.05.001

M3 - Review article

VL - 22

SP - 409

EP - 412

JO - Neurosurgery Clinics of North America

JF - Neurosurgery Clinics of North America

SN - 1042-3680

IS - 3

ER -